Science Current Events | Science News | Brightsurf.com
 

Recent Methotrexate Current Events | Methotrexate News

Page 1 of 2 | 40 Results
Previous0102   Next   
Sort By: Relevance | Page Views
First international guidelines for treatment of psoriatic arthritis
Rheumatologists, dermatologists, and patient advocates have come together to publish the first-ever international guidelines for the treatment of psoriatic arthritis, a disease that mainly affects people who have psoriasis but also some people without it.   view more (2008-10-27)

New Guidelines for Treating Rheumatoid Arthritis
Proven combinations of medicines and the introduction of new anti-arthritis drugs have significantly improved the treatment of rheumatoid arthritis (RA), according to guidelines issued by the American College of Rheumatology and co-authored by physicians at the University of Alabama at Birmingham... view more (2008-07-23)

30 percent RA patients refractory to anti-TNFs achieve disease remission with tocilizumab plus metho
Tocilizumab plus methotrexate showed significant clinical improvements in efficacy and safety in patients with moderate to severe rheumatoid arthritis (RA), who had not adequately responded to anti-tumour necrosis factor (anti-TNF) therapy.   view more (2008-06-16)

Abatacept and infliximab improve clinical response over time in methotrexate-refractory RA patients
New data presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France, show that over half of rheumatoid arthritis patients resistant to methotrexate monotherapy improved when either abatacept or infliximab were added to their methotrexate treatment... view more (2008-06-16)

50 percent of recent onset RA patients become free of signs and symptoms within 36 weeks
At least 50% of recent onset rheumatoid arthritis patients achieve remission (a state free of signs and symptoms) within 36 weeks when following a systematic approach of step-up DMARD treatment in combination with tight control.   view more (2008-06-12)

Gene therapy increases survival for end-stage head and neck cancer
A gene therapy invented at The University of Texas M. D. Anderson Cancer Center is the first to succeed in a U.S. phase III clinical trial for cancer, as announced today at the American Society of Gene Therapy annual meeting in Boston.   view more (2008-05-29)

Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
The first study to investigate the effects of chemotherapy on metastatic breast cancer in women with the BRCA1 or BRCA2 gene mutation has shown that standard chemotherapy works better in these patients than in women without the BRCA1/2 mutation.   view more (2008-04-17)

St. Jude gene study reveals basis of anticancer drug resistance in childhood leukemia
The first analysis of the genetic determinants of resistance to the anti-cancer drug methotrexate in childhood acute lymphoblastic leukemia (ALL) could offer a pathway to predicting such resistance and treatments to overcome it, according to a St. Jude Children's Research Hospital study.   view more (2008-04-16)

Chemotherapy-induced anemia increases risk of local breast cancer recurrence
Patients with breast cancer who developed anemia during chemotherapy had nearly three times the risk of local recurrence as those who did not, according to a study published in the April 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research.   view more (2008-04-01)

Arthritis medications reduce the risk of heart attacks and strokes
Patients prescribed drugs to treat rheumatoid arthritis could be at a reduced risk of heart attacks and strokes, according to a study published today in the open access journal Arthritis Research & Therapy.   view more (2008-03-06)

New findings show Enbrel significantly reduced levels of C-reactive protein
Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein (CRP), a marker of inflammation, in patients with moderate to severe plaque psoriasis following 12 weeks... view more (2008-02-04)

A new view of drugs used to treat rheumatoid arthritis
Powerful drugs used to treat patients with rheumatoid arthritis have a profound, previously unrecognized effect on the immune system, breaking up molecular "training camps" for rogue cells that play an increasingly recognized role in autoimmune diseases like rheumatoid arthritis and lupus.   view more (2008-01-21)

New Actemra data shows significant benefit for patients suffering from rheumatoid arthritis
The innovative new rheumatoid arthritis drug Actemra (tocilizumab) has been shown to significantly improve the signs and symptoms of rheumatoid arthritis (RA) in patients who failed to achieve an adequate response to traditional disease modifying agents (DMARDs).   view more (2007-11-09)

Scientists discover how gold eases pain of arthritis
Scientists at Duke University Medical Center may have solved the mystery surrounding the healing properties of gold - a discovery they say may renew interest in gold salts as a treatment for rheumatoid arthritis and other inflammatory diseases.   view more (2007-10-23)

Cell growth technology promises more successful drug development
Scientists have developed unique technology to grow stem cells and other tissue in the laboratory in conditions similar to the way they grow in the human body.   view more (2007-09-19)

Common rheumatoid arthritis treatment shows potential for diabetes prevention
Far fewer rheumatoid arthritis patients treated with the drug hydroxychloroquine (HCQ) went on to develop diabetes compared to those who never took the drug.   view more (2007-07-11)

First multinational study of Tocilizumab reports in
Nearly half (43.9%) of rheumatoid arthritis (RA) patients receiving tocilizumab 8mg/kg, in addition to ongoing methotrexate therapy experienced a 50% (ACR50) improvement in symptoms at 24 weeks and more than one fifth achieved a 70% symptom improvement.   view more (2007-06-18)

Bone erosion reduced by denosumab in phase 2 trial
reatment with denosumab 60 mg and 180 mg (with background methotrexate) reduces the progression of bone erosion according to results of a 227 patient Phase II trial.   view more (2007-06-18)

Disability from long-term rheumatoid arthritis reduced with biologic treatment
New data demonstrating the safety and efficacy of Enbrel® (etanercept) in the treatment of rheumatoid arthritis (RA) patients over the long-term were presented today at the EULAR (European League Against Rheumatism) congress.   view more (2007-06-13)

Inherited genes linked to toxicity of leukemia therapy
Investigators at St. Jude Children's Research Hospital have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.   view more (2007-05-14)

Role for proteomics in identifying hematologic malignancies
Scientists have identified a set of biomarkers that could help clinicians identify a group of hematologic malignancies known as myelodysplastic syndromes (MDS), which affect approximately 300,000 individuals worldwide and often progress to acute myeloid leukemia.   view more (2007-01-11)

Chemo drugs for treating breast cancer may cause changes in cognitive function
A new study investigating the effects of chemotherapy on cognitive function in mice has confirmed what many cancer patients receiving treatment have often complained about - a decline in their memory and other cognitive functions, sometimes characterized as "chemobrain".   view more (2006-10-30)

Arthritis Drug Helps Debilitating Inflammatory Disease
For children and young adults who suffer from a rare and debilitating disorder called neonatal-onset multisystem inflammatory disease (NOMID), a drug called anakinra brings marked improvement both in symptoms and the inflammation underlying the disease, a new study shows.   view more (2006-08-11)

NICE gives backing for the use of advanced biological therapies to treat severe psoriasis
The UK National Institute for Health and Clinical Excellence (NICE) has today issued guidance for the use of the targeted biological therapies, Enbrel® (etanercept) and Raptiva® (efalizumab), to treat adult patients with severe plaque psoriasis.   view more (2006-07-27)

New evidence shows Rituximab halts damage to joints
New data, presented today at the Annual European Congress of Rheumatology show for the first time that a rheumatoid arthritis (RA) treatment, rituximab, is able to significantly inhibit the structural damage to joints caused by RA in patients who have long-standing disease and an inadequate... view more (2006-06-23)
Page 1 of 2 | 40 Results
Previous0102   Next   
Sort By: Relevance | Page Views
© 2008 BrightSurf.com